30-07-2010: CT Atlantic AG, a biotechnology company focused on cancer treatment by human-derived antibodies, announced the appointment of Michael Höcker to CEO. In addition, Cara Lerner has been appointed to COO.
Michael Höcker most recently served as a Global Medical Director at Hoffmann-La Roche Ltd. (Basel). Prior to this he held executive positions of increasing responsibility at AstraZeneca Ltd. including VP Medical for the German market. Before joining the pharmaceutical industry, he was an Associate Professor of Medicine at the Charité in Berlin, where also he headed an independent research group focussing on the molecular biology of cancer angiogenesis.
Prof. Höcker holds an MD degree from the University of Göttingen and received his scientific and clinical training at the Massachusetts General Hospital, Harvard Medical School, Boston and the Charité in Berlin. He is a board certified Internist and (co-)author of more than 50 peer-reviewed publications and several patents and patent applications.
Cara Lerner, an experienced pharmaceutical program and portfolio manager with a background as a researcher in immunology, adds essential expertise in the management of technology development programs and budget tracking and forecasting. Cara Lerner originally joined CT Atlantic in 2009 as Head of Program Management. Previously, Ms. Lerner was with Merck Research Laboratories, Merck & Co., Inc., where she was a Program Manager, focusing on innovative technology evaluation and management of domestic and international vendors.
Ms. Lerner holds a Bachelor of Science in Biology from Tufts University, USA and a Masters Degree in Immunology from University of Washington, USA. She is a Certified Associate in Project Management (CAPM).
CT Atlantic AG presented preclinical proof of concept data for its lead HD-MAB® CTA001.12D7 that support its advancement into clinical development for the treatment of cancer.In vivo studies demonstrated that CTA001.12D7 — the first human-derived antibody against cancer-testis (CT) antigen ... more
CT Atlantic AG announced the appointment of Dr. Thomas Lander to its board of directors. Thomas Lander provides CT Atlantic with long-standing, global pharmaceutical experience in early through late stage drug development and in regulatory affairs.
Dr. Lander was previously Managing Direct ... more
CT Atlantic AG, a biotechnology company focused on cancer treatment by human-derived antibodies, announced the appointment of Michael Höcker to CEO. In addition, Cara Lerner has been appointed to COO.
Michael Höcker most recently served as a Global Medical Director at Hoffmann-La Roche Ltd ... more
CT Atlantic AG is a biotech company focused on the identification and development of human-derived monoclonal antibodies – HD-MABs™ as novel therapeutics for the treatment of cancer.
CT Atlantic is a spin-off of the University of Zurich (Zurich, Switzerland) and the Ludwig Institute for Ca ... more